Alvotech ALVO, a commercial-stage company developing and manufacturing biosimilar medicines for patients worldwide, is ...

Alvotech (ALVO) has been on a downward spiral lately with significant selling pressure. After declining 6.6% over the past four weeks, the stock looks well positioned for a trend reversal as it is now ...

— Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global ...

Alvotech partnered with Kashiv BioSciences for the development of the proposed Xolair® biosimilar, which is referred to as AVT23 by Alvotech and as ADL-018 by Kashiv Biosciences. Use of trademarks ...

Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab) Provided by GlobeNewswire Jun 4, 2025, 11:55:00 PM ...

Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million ...

Alvotech joined the Nasdaq on June 16th 2022, completing a business combination with the Special Purpose Acquisition Company ("SPAC") Oaktree Acquisition Corp that included a $175m private ...

REYKJAVIK, Iceland--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for ...

Alvotech has entered into an agreement with the Lenders for a senior secured first lien term loan facility of up to $965 million, in two tranches. The first tranche, a first lien $900 million term ...

Alvotech Holdings SA tapped Cooley to advise it on its blank-check merger, which will create a pharmaceutical company worth roughly $2.25 billion.

Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities.